Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Use of transcranial direct current stimulation for the treatment of auditory hallucinations of schizophrenia - a systematic review.

Pondé PH, de Sena EP, Camprodon JA, de Araújo AN, Neto MF, DiBiasi M, Baptista AF, Moura LM, Cosmo C.

Neuropsychiatr Dis Treat. 2017 Feb 1;13:347-355. doi: 10.2147/NDT.S122016. Review.

2.

Association of polygenic risk for major psychiatric illness with subcortical volumes and white matter integrity in UK Biobank.

Reus LM, Shen X, Gibson J, Wigmore E, Ligthart L, Adams MJ, Davies G, Cox SR, Hagenaars SP, Bastin ME, Deary IJ, Whalley HC, McIntosh AM.

Sci Rep. 2017 Feb 10;7:42140. doi: 10.1038/srep42140.

3.

Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria.

Igbinomwanhia NG, Olotu SO, James BO.

Ther Adv Psychopharmacol. 2017 Jan;7(1):3-10. doi: 10.1177/2045125316672134.

4.

Dental caries status of patients with schizophrenia in Seville, Spain: a case-control study.

Velasco-Ortega E, Monsalve-Guil L, Ortiz-Garcia I, Jimenez-Guerra A, Lopez-Lopez J, Segura-Egea JJ.

BMC Res Notes. 2017 Jan 18;10(1):50. doi: 10.1186/s13104-016-2368-9.

5.

Effect on the expression of drd2 and drd3 after neonatal lesion in the lymphocytes, nucleus accumbens, hippocampus and prefrontal cortex: comparative analysis between juvenile and adult Wistar rats.

Genis-Mendoza AD, Tovilla-Zárate CA, López-Narvaez L, Mendoza-Lorenzo P, Ostrosky-Wegman P, Nicolini H, González-Castro TB, Hernández-Diaz Y.

Hereditas. 2016 Nov 22;153:13. doi: 10.1186/s41065-016-0018-9.

6.

Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M.

Am Health Drug Benefits. 2016 Oct;9(7):399-410.

7.

The impact of gender on treatment effectiveness of body psychotherapy for negative symptoms of schizophrenia: A secondary analysis of the NESS trial data.

Savill M, Orfanos S, Bentall R, Reininghaus U, Wykes T, Priebe S.

Psychiatry Res. 2017 Jan;247:73-78. doi: 10.1016/j.psychres.2016.11.020.

PMID:
27871030
8.

Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders.

Rutkowski TP, Schroeder JP, Gafford GM, Warren ST, Weinshenker D, Caspary T, Mulle JG.

J Neurosci Res. 2017 May;95(5):1144-1160. doi: 10.1002/jnr.23970. Review.

PMID:
27859486
9.

Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders.

Crider A, Pillai A.

J Pharmacol Exp Ther. 2017 Jan;360(1):48-58.

PMID:
27789681
10.

Mortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in Poland.

Zagozdzon P, Goyke B, Wrotkowska M.

Drugs Real World Outcomes. 2016 Sep;3(3):345-351.

12.

Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.

Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH.

Diabetes Obes Metab. 2017 Feb;19(2):162-171. doi: 10.1111/dom.12795.

13.

The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.

Crider A, Pillai A.

Curr Behav Neurosci Rep. 2016 Jun;3(2):154-164.

PMID:
27695666
14.

Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia.

Genovese G, Fromer M, Stahl EA, Ruderfer DM, Chambert K, Landén M, Moran JL, Purcell SM, Sklar P, Sullivan PF, Hultman CM, McCarroll SA.

Nat Neurosci. 2016 Nov;19(11):1433-1441. doi: 10.1038/nn.4402.

PMID:
27694994
15.

Brain development in adolescents at ultra-high risk for psychosis: Longitudinal changes related to resilience.

de Wit S, Wierenga LM, Oranje B, Ziermans TB, Schothorst PF, van Engeland H, Kahn RS, Durston S.

Neuroimage Clin. 2016 Aug 13;12:542-549.

16.

Brexpiprazole: A New Treatment Option for Schizophrenia.

Scarff JR.

Innov Clin Neurosci. 2016 Aug 1;13(7-8):26-9. Review.

17.

Gene expression elucidates functional impact of polygenic risk for schizophrenia.

Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, Ruderfer DM, Oh EC, Topol A, Shah HR, Klei LL, Kramer R, Pinto D, Gümüş ZH, Cicek AE, Dang KK, Browne A, Lu C, Xie L, Readhead B, Stahl EA, Xiao J, Parvizi M, Hamamsy T, Fullard JF, Wang YC, Mahajan MC, Derry JM, Dudley JT, Hemby SE, Logsdon BA, Talbot K, Raj T, Bennett DA, De Jager PL, Zhu J, Zhang B, Sullivan PF, Chess A, Purcell SM, Shinobu LA, Mangravite LM, Toyoshiba H, Gur RE, Hahn CG, Lewis DA, Haroutunian V, Peters MA, Lipska BK, Buxbaum JD, Schadt EE, Hirai K, Roeder K, Brennand KJ, Katsanis N, Domenici E, Devlin B, Sklar P.

Nat Neurosci. 2016 Nov;19(11):1442-1453. doi: 10.1038/nn.4399.

PMID:
27668389
18.

Lack of Gender-Related Differences in Childhood-Onset Schizophrenia.

Ordóñez AE, Loeb FF, Zhou X, Shora L, Berman RA, Broadnax DD, Gochman P, Liu S, Rapoport JL.

J Am Acad Child Adolesc Psychiatry. 2016 Sep;55(9):792-9. doi: 10.1016/j.jaac.2016.05.022.

19.

Improving the Physical Health Monitoring of City & Hackney Assertive Outreach Service Patients.

Akyuz E, Jain A, Phelan D, Gupta S.

BMJ Qual Improv Rep. 2016 Feb 25;5(1). pii: u210108.w4174. doi: 10.1136/bmjquality.u210108.w4174.

20.

Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran.

Shakeri J, Karimi K, Farnia V, Golshani S, Alikhani M.

Oman Med J. 2016 Jul;31(4):270-5. doi: 10.5001/omj.2016.53.

Supplemental Content

Support Center